Adverum is developing a pipeline of intravitreal single-administration gene therapies with the aspiration of developing functional cures to restore vision and prevent blindness.
This white paper shares practical solutions to purification and analytical challenges in PDC manufacturing, along with insights into synthesizing complex peptides, oligonucleotides, and conjugates.
EVP & COO, Todd Nelson, reflects on Porton J-STAR's defining milestones, global network strategy, and what’s ahead as the company enters its third decade.
Drawing insights from industry leaders and results from an in-depth Contract Pharma reader survey, this eBook provides a timely snapshot of what matters most to today’s packaging decision-makers.
Sentry BioPharma Services, Inc. (Sentry US) protects product SISPQ by offering compliant pharmaceutical services, including cGMP temperature-controlled storage, controlled substance management (CS III-V), clinical/commercial labeling and secondary packaging. Sentry also provides import/export optimization by leveraging our end-to-end GxP logistics, global distribution and Foreign Trade Zone expertise. Sentry’s status as a US Foreign Trade Zone enables products from outside the United States to be received and held within cGMP storage, pending approval for importation from the FDA, CBP and DEA. Sentry is VAWD accredited, licensed in all US states and inspected by the FDA, along with numerous international authorities. Sentry’s newest facility in Columbus, IN provides stock splitting risk mitigation services and will offer additional cGMP offerings in 2026.
Vetter is a leading and independent global CDMO for the aseptic production of injectables. Its roots and headquarters are in Ravensburg, Germany. Vetter has been a stable, reliable family-owned company since its establishment as a pharmacy in 1950, now with more than 7,300 skilled and dedicated employees.
